Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03361865
Title Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

ureter transitional cell carcinoma

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Epacadostat + Pembrolizumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.